$664MTake-privateHealthcare & Life Sciences
Webster Equity to take Lifecore Biomedical private in deal worth up to $664M
Lifecore Biomedical agreed to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of performance milestones. Shareholders receive $6.28 per share in cash at closing plus one non-tradable contingent right. Management framed the deal as funding the CDMO's next growth phase, with multiple customer programs potentially commercializing by the end of 2028.
Why it matters: Another small-cap pharma services business heads private as sponsors hunt for CDMO capacity at discounted public valuations.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.